Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00683670 · ClinicalTrials.gov registry record · Phase 1
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00683670: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT00683670 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00683670, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate a method of using dendritic cells (a kind of white blood cell) as a vaccine to stimulate your own immune system to react to your melanoma cells.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL Mature dendritic cell vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-08 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00683670
The ClinicalTrials.gov registry entry for NCT00683670 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cyclophosphamide is the first listed.
NCT00683670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00683670 about?
NCT00683670 is a clinical study titled "Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma". The purpose of this study is to investigate a method of using dendritic cells (a kind of white blood cell) as a vaccine to stimulate your own immune system to react to your melanoma cells.
What is the current status of trial NCT00683670?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2008-08. Estimated completion is 2016-06.
What interventions are being tested in trial NCT00683670?
The interventions under investigation include: cyclophosphamide (DRUG), Mature dendritic cell vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00683670?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.